Ares Systematic Credit’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-6,196
Closed -$407K 248
2026
Q1
$407K Sell
6,196
-3,316
-35% -$235K 0.32% 88
2025
Q4
$723K Buy
+9,512
New +$691K 0.59% 54

Other funds holding PTCT

Ares Systematic Credit's PTCT Position: Q2 2026 in Review

Ares Systematic Credit sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 6,196 shares — an estimated $407K sold.

Ares Systematic Credit first reported a position in PTCT in Q4 2025 and held it in 2 quarters. The position peaked at $723K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Ares Systematic Credit reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ares Systematic Credit sold 6,196 PTC Therapeutics shares in Q2 2026, an estimated $407K.
  • Ares Systematic Credit first reported a position in PTC Therapeutics in Q4 2025 and held it in 2 quarters.
  • Ares Systematic Credit's PTC Therapeutics position peaked at $723K in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Ares Systematic Credit's 13F filing for Q2 2026, filed 14 Aug 2026.